Literature DB >> 1980314

Combination therapy of rheumatoid arthritis--rationale and overview.

I A Jaffe1.   

Abstract

Currently available therapeutic agents for the treatment of rheumatoid arthritis are unsatisfactory for many patients, due either to inefficacy, loss of effectiveness with time, or toxicity. One approach is to study drugs in combination, at lower than usual dosages of each, in order to achieve greater efficacy with fewer adverse reactions. To aid in this review of published trials, the various combinations have been arbitrarily divided into combinations of cytotoxic (antiproliferative) drugs with each other, and combinations of noncytotoxic drugs. Of the noncytotoxic combinations, intramuscular gold with D-penicillamine appeared to offer the best results without increased side effects when compared to each one used alone. The most promising cytotoxic combination was methotrexate with azathioprine.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1980314

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN: 0380-0903


  4 in total

Review 1.  Management of rheumatic diseases in children.

Authors:  B H Athreya
Journal:  Indian J Pediatr       Date:  1996 May-Jun       Impact factor: 1.967

2.  The national database of the German Collaborative Arthritis Centres: II. Treatment of patients with rheumatoid arthritis.

Authors:  A Zink; J Listing; M Niewerth; H Zeidler
Journal:  Ann Rheum Dis       Date:  2001-03       Impact factor: 19.103

Review 3.  A risk-benefit assessment of slow-acting antirheumatic drugs in rheumatoid arthritis.

Authors:  A A Kalla; A F Tooke; E Bhettay; O L Meyers
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

Review 4.  Clinical pharmacology and modification of autoimmunity and inflammation in rheumatoid disease.

Authors:  R Luqmani; C Gordon; P Bacon
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.